Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab-based extension study in multiple myeloma
jRCT2031230009Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Primary endpoint: Number of participants with treatment-emergent adverse events. Started May 2023; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031230009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230009.